Literature DB >> 36128485

Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: CON.

Swetha Rani Kanduri1, Juan Carlos Q Velez1,2.   

Abstract

Entities:  

Keywords:  CONS; acute interstitial nephritis; acute kidney injury; acute kidney injury and ICU nephrology; causality; debates; immune checkpoint inhibitors; immune-related adverse effects; rechallenge

Mesh：

Substances：

Year:  2021        PMID： 36128485      PMCID： PMC9438430          DOI： 10.34067/KID.0003902021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  16 in total

1.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Authors:  Mario Sznol; Pier Francesco Ferrucci; David Hogg; Michael B Atkins; Pascal Wolter; Massimo Guidoboni; Celeste Lebbé; John M Kirkwood; Jacob Schachter; Gregory A Daniels; Jessica Hassel; Jonathan Cebon; Winald Gerritsen; Victoria Atkinson; Luc Thomas; John McCaffrey; Derek Power; Dana Walker; Rafia Bhore; Joel Jiang; F Stephen Hodi; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2017-09-15       Impact factor: 44.544

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

3.  Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.

Authors:  Sandhya Manohar; Ranine Ghamrawi; Madhuri Chengappa; Busra N Bacik Goksu; Lisa Kottschade; Heidi Finnes; Roxana Dronca; Konstantinos Leventakos; Joerg Herrmann; Sandra M Herrmann
Journal:  Kidney360       Date:  2020-01-07

4.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.

Authors:  Akbar K Waljee; Mary A M Rogers; Paul Lin; Amit G Singal; Joshua D Stein; Rory M Marks; John Z Ayanian; Brahmajee K Nallamothu
Journal:  BMJ       Date:  2017-04-12

5.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Authors:  Omar Mamlouk; Umut Selamet; Shana Machado; Maen Abdelrahim; William F Glass; Amanda Tchakarov; Lillian Gaber; Amit Lahoti; Biruh Workeneh; Sheldon Chen; Jamie Lin; Noha Abdel-Wahab; Jean Tayar; Huifang Lu; Maria Suarez-Almazor; Nizar Tannir; Cassian Yee; Adi Diab; Ala Abudayyeh
Journal:  J Immunother Cancer       Date:  2019-01-06       Impact factor: 13.751

6.  Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.

Authors:  Marion Allouchery; Thomas Lombard; Mickael Martin; Franck Rouby; Marion Sassier; Celia Bertin; Marina Atzenhoffer; Ghada Miremont-Salame; Marie-Christine Perault-Pochat; Mathieu Puyade
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

7.  Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations.

Authors:  Mark A Perazella; Ben Sprangers
Journal:  Clin Kidney J       Date:  2021-03-10

8.  Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.

Authors:  Busra Isik; Mariam P Alexander; Sandhya Manohar; Lisa Vaughan; Lisa Kottschade; Svetomir Markovic; John Lieske; Aleksandra Kukla; Nelson Leung; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2021-02-02

9.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

Authors:  Frank B Cortazar; Zoe A Kibbelaar; Ilya G Glezerman; Ala Abudayyeh; Omar Mamlouk; Shveta S Motwani; Naoka Murakami; Sandra M Herrmann; Sandhya Manohar; Anushree C Shirali; Abhijat Kitchlu; Shayan Shirazian; Amer Assal; Anitha Vijayan; Amanda DeMauro Renaghan; David I Ortiz-Melo; Sunil Rangarajan; A Bilal Malik; Jonathan J Hogan; Alex R Dinh; Daniel Sanghoon Shin; Kristen A Marrone; Zain Mithani; Douglas B Johnson; Afrooz Hosseini; Deekchha Uprety; Shreyak Sharma; Shruti Gupta; Kerry L Reynolds; Meghan E Sise; David E Leaf
Journal:  J Am Soc Nephrol       Date:  2020-01-02       Impact factor: 10.121

Review 10.  Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.

Authors:  John Haanen; Marc Ernstoff; Yinghong Wang; Alexander Menzies; Igor Puzanov; Petros Grivas; James Larkin; Solange Peters; John Thompson; Michel Obeid
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.